Lys668
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Tri-methylation Site Page: > Lys668  -  NFAT5 (human)

Site Information
KQQQIQPkAYNPETL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1884021300

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 )
Relevant cell line - cell type - tissue:
LN229 (glial) ( 1 ) , U-251 MG (glial) ( 1 ) , U87MG (glial) ( 1 )

Upstream Regulation
Regulatory protein:
EZH2 (human) ( 1 )
Treatments:
EGF ( 1 )

Downstream Regulation
Effects of modification on NFAT5:
activity, induced ( 1 ) , intracellular localization ( 1 ) , molecular association, regulation ( 1 ) , protein stabilization ( 1 )
Effects of modification on biological processes:
transcription, induced ( 1 )
Induce interaction with:
KPNB1 (human) ( 1 ) , STAM1 (human) ( 1 )
Inhibit interaction with:
TRAF6 (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
glioblastoma multiforme ( 1 )

References 

1

Li Y, et al. (2023) Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. Nat Commun 14, 4062
37429858   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.